Biogen price target lowered to $310 from $350 at Canaccord

Canaccord lowered the firm’s price target on Biogen to $310 from $350 and keeps a Buy rating on the shares. The firm gets the sense that new management is acutely tuned into getting the right components in place to drive growth that is decoupled from a declining legacy revenue base, and getting costs right in the process.